Management of NVAF:
From Evidence to Practice
Wednesday, 11 December 2024
Middle East, Russia and Africa
(MERA) Session
Professor Derek Connolly
Consultant Cardiologist,
The Midland Metropolitan University Hospital,
Birmingham City Hospital & Sandwell Hospital,
Sandwell & West Birmingham NHS Trust,
United Kingdom
Country/region
Morocco, Nigeria
16:30 – 17:30
South Africa, Egypt, Lebanon
17:30 – 18:30
Bahrain, Iraq, Jordan, Kuwait,
Qatar, Russia*, Saudi Arabia, Turkey
18:30 – 19:30
Oman, United Arab Emirates
19:30 – 20:30
*time zone based on Moscow, Standard Time (UTC +3)
Wednesday, 11 December 2024
Asia Session
Professor Derek Connolly
Consultant Cardiologist,
The Midland Metropolitan University Hospital,
Birmingham City Hospital & Sandwell Hospital,
Sandwell & West Birmingham NHS Trust,
United Kingdom
Country/region
Pakistan
16:30 – 17:15
India
17:00 – 17:45
Indonesia*, Thailand, Vietnam
18:30 – 19:15
Hong Kong, Malaysia, Philippines,
Singapore, Taiwan
19:30 – 20:15
*time zone based on Western Indonesia (UTC +7)
Wednesday, 11 December 2024
Latin America (LATAM)
Session
Professor Derek Connolly
Consultant Cardiologist,
The Midland Metropolitan University Hospital,
Birmingham City Hospital & Sandwell Hospital,
Sandwell & West Birmingham NHS Trust,
United Kingdom
Country/region
Costa Rica, Guatemala, Mexico*
16:30 – 17:15
Colombia, Ecuador**, Panama, Peru
17:30 – 18:15
Bolivia, Dominican Republic
18:30 – 19:15
Argentina, Brazil †, Chile ‡, Paraguay, Uruguay
19:30 – 20:15
*time zone based on Mexico City, Central Standard Time (UTC -6)
**time zone based on Quito, Ecuador Time (UTC -5)
†time zone based on São Paulo, Brasilia Time (UTC -3)
‡time zone based on Santiago, Chile Summer Time (UTC -3)
OBJECTIVES
Gain insights into the latest scientific evidence for
managing NVAF patients, including those with
specific clinical or demographic characteristics or
comorbidities
Discuss data from studies on safe and effective anticoagulation
in patients with NVAF, including those with specific clinical or
demographic characteristics or comorbidities, and how this
influences clinical decision-making
Review the 2024 ESC atrial fibrillation guidelines on stroke
risk assessment and anticoagulation management for
patients with NVAF, with specific clinical or demographic
characteristics or comorbidities
AGENDA
2024 ESC Guidelines for NVAF in Special
Populations
Management for NVAF in Special Populations